Pfizer: Advancing the development of the once-daily oral GLP-1 weight loss drug Danuglipron. Studies show that Danuglipron has good pharmacokinetic properties. Dose optimization studies will be conducted in the second half of 2024.
辉瑞：正在推进每日一次GLP-1口服减肥药Danuglipron的研发
Pfizer: Advancing the development of the once-daily oral GLP-1 weight loss drug Danuglipron.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.